Article ID,Publication Year,Reference,US$/QALY *,Ratio Description,PubMed ID,Target Population,Intervention Description,Title,Comparator Description,Impact
2019-01-32532,2019,Turcu-Stiolica 2019 Front Pharmacol,1100,incobotulinumtoxin-a VERSUS Standard/Usual Care- conventional therapy program alone IN Specific disease- post-stroke spasticity; Age- Adult; Gender- Both; Country- Romania; Other- post-stroke upper limb spasticity.,32009947,Specific disease- post-stroke spasticity; Age- Adult; Gender- Both; Country- Romania; Other- post-stroke upper limb spasticity.,incobotulinumtoxin-a,Cost-Utility Analysis of Incobotulinumtoxin-A Compared With Conventional Therapy  in the Management of Post-Stroke Spasticity in Romania.,Standard/Usual Care- conventional therapy program alone,NE
2018-01-28565,2018,Suijkerbuijk 2018 PLoS One,6000,Both Hepatitis B and Hepatitis C Screening VERSUS None IN Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Romania.,30408079,Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Romania.,Both Hepatitis B and Hepatitis C Screening,Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.,None,NE
2018-01-28565,2018,Suijkerbuijk 2018 PLoS One,6300,Hepatitis C Screening VERSUS None IN Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Romania.,30408079,Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Romania.,Hepatitis C Screening,Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.,None,NE
2018-01-28565,2018,Suijkerbuijk 2018 PLoS One,6900,Hepatitis B Screening VERSUS None IN Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Romania.,30408079,Healthy; Age- Unknown; Gender- Both; Country- Netherlands; Other- Migrants from Romania.,Hepatitis B Screening,Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.,None,NE
2009-01-05354,2009,Sava 2009 J Clin Psychol,2100,"Cognitive Therapy: Maximum of 20 individual 50-min therapy sessions or a maximum of 20 individual 20-min pharmacotherapy sessions, over the 14 weeks allowed for treatment VERSUS No treatment IN Patients diagnosed with major depressive disorder within the Romanian healthcare system.",19051275,Patients diagnosed with major depressive disorder within the Romanian healthcare system.,"Cognitive Therapy: Maximum of 20 individual 50-min therapy sessions or a maximum of 20 individual 20-min pharmacotherapy sessions, over the 14 weeks allowed for treatment","Cost-effectiveness and cost-utility of cognitive therapy, rational emotive behavioral therapy, and fluoxetine (Prozac) in treating depression: a randomized clinical trial.",No treatment,NE
2009-01-05354,2009,Sava 2009 J Clin Psychol,2200,"Rational Emotive Behavioral Therapy: maximum of 20 individual 50-min therapy sessions or a maximum of 20 individual 20-min pharmacotherapy sessions, over the 14 weeks allowed for treatment VERSUS No treatment IN Patients diagnosed with major depressive disorder within the Romanian healthcare system.",19051275,Patients diagnosed with major depressive disorder within the Romanian healthcare system.,"Rational Emotive Behavioral Therapy: maximum of 20 individual 50-min therapy sessions or a maximum of 20 individual 20-min pharmacotherapy sessions, over the 14 weeks allowed for treatment","Cost-effectiveness and cost-utility of cognitive therapy, rational emotive behavioral therapy, and fluoxetine (Prozac) in treating depression: a randomized clinical trial.",No treatment,NE
2009-01-05354,2009,Sava 2009 J Clin Psychol,2900,"Fluoxetine (Prozac) Therapy: Initial 50-min meeting with the psychiatrist, subsequent sessions 20 min. once per week. Initial dose of 10 mg/day was increased to 20 mg/d during Week 1 and to 40 mg/d by Weeks 2 to 12. The maximum dosage allowed was 60 to 80 mg/d (M550.1, SD54.5). During Weeks 12 to 14, dosage was reduced again to 20 mg/d for 53% of participants whose depression improved VERSUS No treatment IN Patients diagnosed with major depressive disorder within the Romanian healthcare system.",19051275,Patients diagnosed with major depressive disorder within the Romanian healthcare system.,"Fluoxetine (Prozac) Therapy: Initial 50-min meeting with the psychiatrist, subsequent sessions 20 min. once per week. Initial dose of 10 mg/day was increased to 20 mg/d during Week 1 and to 40 mg/d by Weeks 2 to 12. The maximum dosage allowed was 60 to 80 mg/d (M550.1, SD54.5). During Weeks 12 to 14, dosage was reduced again to 20 mg/d for 53% of participants whose depression improved","Cost-effectiveness and cost-utility of cognitive therapy, rational emotive behavioral therapy, and fluoxetine (Prozac) in treating depression: a randomized clinical trial.",No treatment,NE
1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
